Seeking Alpha
View as an RSS Feed

SA Editor Douglas W. House  

View SA Editor Douglas W. House's Comments BY TICKER:
Latest comments  |  Highest rated
  • Receptos ulcerative colitis candidate successful in Phase 2 study [View news story]
    The bulk of healthcare news breaks in the am, mostly premarket. Since I can't post everything at once, there is a queue.
    Apr 16, 2015. 11:19 AM | 1 Like Like |Link to Comment
  • Healthcare ratings roundup [View news story]
    Thanks. I updated CLVS.
    Apr 15, 2015. 03:28 PM | Likes Like |Link to Comment
  • J&J Q1 earnings off 9%; guidance lowered [View news story]
    Just like I cherry picked the Product Leaders?
    Apr 14, 2015. 11:06 AM | Likes Like |Link to Comment
  • J&J Q1 earnings off 9%; guidance lowered [View news story]
    Q1 net income is down 8.6% from Q1 2014 (4,320/4,727). It lowered its 2015 EPS guidance, which is the only guidance provided in the press release, to $6.04 - 6.19 from $6.12 - 6.27.
    Apr 14, 2015. 10:35 AM | 1 Like Like |Link to Comment
  • Arena secures new Belviq patent; Eisai cuts sales force [View news story]
    Sorry, I meant regulatory filing, not PR.
    Apr 10, 2015. 10:38 AM | 1 Like Like |Link to Comment
  • Arena secures new Belviq patent; Eisai cuts sales force [View news story]
    My take on the PR is Eisai is restructuring its operations, i.e. realigning responsibilities. Now, only 90 Eisai reps will be promoting (sharing sales time with two other products - not great news) along with 230 independent reps (also sharing sales time with another unnamed product - not great news either). The 25% reduction in workforce is part of its restructuring across various functions, not just sales.
    Apr 10, 2015. 10:33 AM | 2 Likes Like |Link to Comment
  • Healthcare stock screen of the month: Price extended, poor fundamentals [View news story]
    Tompkins: Fundamentals pertain to financial results. All the companies listed have little/no sales, no profits, negative cash flow ops.
    Apr 8, 2015. 05:11 PM | 4 Likes Like |Link to Comment
  • Healthcare stock screen of the month: Price extended, poor fundamentals [View news story]
    The Pro: It's a screen, not a detailed analysis.
    Apr 8, 2015. 05:09 PM | 2 Likes Like |Link to Comment
  • Healthcare stock screen of the month: Price extended, poor fundamentals [View news story]
    st66: No bias. The stocks are just extended at least 30% above the 50-d MA.
    Apr 8, 2015. 05:08 PM | 2 Likes Like |Link to Comment
  • Healthcare stock screen of the month: Price extended, poor fundamentals [View news story]
    Folks, this is merely a screen of healthcare stocks based on the criteria listed in the post. I intend to do one of these every month or so on different criteria to provide subscribers with a list of tickers that may warrant further research. It's not meant to be a detailed Buy/Sell list. There will be distinguishing characteristics regarding every stock. Your decision to buy, hold or sell is, of course, yours based on your own research.
    Apr 8, 2015. 01:55 PM | 1 Like Like |Link to Comment
  • Cytori's ECCS-50 tagged an Orphan Drug in Europe [View news story]
    Thanks for the additional info. Cytori's PR was a bit on the promotional side so that's why I omitted "ground-breaking." As always, lots happening in the stem cell arena.
    Apr 8, 2015. 11:34 AM | 1 Like Like |Link to Comment
  • Organovo inks collaboration deal with L'Oreal USA [View news story]
    There is a need for "life-like" skin models for cosmetic product makers. The closer the models are to the real thing, the better the data re toxicology, absorption, half-life, etc. If the models are good enough, it could theoretically eliminate the need to use live animals, especially for toxic dose testing. Much work needs to be done, though, to prove their worth.
    Apr 7, 2015. 09:57 AM | 7 Likes Like |Link to Comment
  • Aduro Biotech on deck for IPO [View news story]
    Hasn't been announced yet. Typically, a press release goes out a few days before.
    Apr 7, 2015. 09:51 AM | Likes Like |Link to Comment
  • Cytori's ECCS-50 tagged an Orphan Drug in Europe [View news story]
    Orphan Drug status means that the EC will not approve another drug for the specific indication for ten years (in the U.S., it's seven years). It's meant to incentivize companies to develop therapies for under-served diseases, occurring in <200K people.
    Apr 7, 2015. 09:49 AM | 1 Like Like |Link to Comment
  • Ohr Pharma shares will be <$3 today but Roth maintains "Buy" with $30 PT [View news story]
    Pharma: Thanks for the comment. I don't disagree with your assessment. The 2/3 market comment was just a reflection on what was found in the Phase 2. My point was that the analyst should reduce his price target just based on that even if he maintains his long-term optimism.
    Mar 27, 2015. 01:05 PM | 1 Like Like |Link to Comment
COMMENTS STATS
694 Comments
727 Likes